Novo Nordisk’s weight loss drug semaglutide found to improve wellbeing
New results from a Phase IIIa study demonstrate benefits of drug for people with obesity ‘beyond weight loss’
Read More
Tag: wellbeing
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
